BiBBInstruments AB (BIBB) Fair Value & Analysis
Healthcare · SE · Market cap 112M SEK
Fair value as of: Aug 2, 2026
From 1 valuation models · updated today
Share price +35.4% over the past month.
Below-average quality, and the price sits another 54% above our fair value.
What matters now
- The price sits above even our optimistic bull case (kr 0.4080). The favourable scenario is already priced in.
- Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
60‑month range kr 0.3820 – kr 10.60 · fair‑value band kr 0.2465 – kr 0.4080 · the kr 0.6960 price screens above the kr 0.3230 fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
BiBBInstruments AB (BIBB) currently trades at kr 0.6960, while our model-based Fair Value estimate is kr 0.3230, implying the stock looks roughly 53.6% overvalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 476K SEK. Revenue grew 192.3% year over year. It earns a return on equity of -41.0%. Fundamentals as of Aug 2, 2026
Our scenario range runs from kr 0.2465 (bear case) to kr 0.4080 (bull case); at kr 0.6960, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -54%, BIBB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BiBBInstruments AB, a medical technology company, develops and markets electrically powered endoscopic biopsy systems in the United States and Europe. The company offers EndoDrill which enables tissue sampling, with the aim of improving diagnostics in several common cancers, including those affecting the pancreas, stomach, liver, lungs, and urinary bladder.
Full company description
BiBBInstruments AB, a medical technology company, develops and markets electrically powered endoscopic biopsy systems in the United States and Europe. The company offers EndoDrill which enables tissue sampling, with the aim of improving diagnostics in several common cancers, including those affecting the pancreas, stomach, liver, lungs, and urinary bladder. It also provides EndoDrill GI which used for endoscopic ultrasound; EndoDrill EBUS is used in the airways during endobronchial ultrasound (EBUS); and EndoDrill URO that is used with a standard cystoscope for sampling of muscle-invasive bladder cancer. The company was incorporated in 2013 and is headquartered in Lund, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
BiBBInstruments AB reported revenue of kr 401K in FY2025 versus kr 0 in FY2022. Reported net income was −kr 14.6M in FY2025.
BIBB sits 54% above fair value. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 400 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare BiBBInstruments AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BiBBInstruments AB (BIBB) overvalued or undervalued?
What is the fair value of BIBB?
What is the quality score of BIBB?
What is the revenue of BiBBInstruments AB (BIBB)?
What is the net profit margin of BIBB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BiBBInstruments AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.